Home>Topics>Stocks>GlaxoSmithKline PLC

GlaxoSmithKline PLC GSK

  1. All
  2. Commentary
  3. Headlines
    1. Fitch Affirms GlaxoSmithKline PLC at 'A+'; Revises Outlook to Negative

      Headlines

      Wed, 17 Dec 2014

      the rating agency) LONDON, December 17 (Fitch) Fitch Ratings has affirmed UK-based pharmaceuticals company GlaxoSmithKline PLC 's (GSK) Long-term Issuer Default Rating (IDR) and senior unsecured rating at 'A+'. The Outlook has

    2. GlaxoSmithKline fires executive who raised race complaint in South Africa: Bloomberg

      Headlines

      Thu, 27 Nov 2014

      (Reuters) - Britain's biggest drugmaker, GlaxoSmithKline Plc , fired an executive from its South African unit for refusing to appear for a performance review, which was called a week after

    3. GlaxoSmithKline fires executive who raised race complaint in South Africa -Bloomberg

      Headlines

      Thu, 27 Nov 2014

      Nov 27 (Reuters) - Britain's biggest drugmaker, GlaxoSmithKline Plc , fired an executive from its South African unit for refusing to appear for a performance review, which was called a week after

    4. ChemoCentryx says partner GSK returns rights to bowel disease drug

      Headlines

      Wed, 18 Sep 2013

      Sept 18 (Reuters) - ChemoCentryx Inc said partner GlaxoSmithKline Plc returned the rights to its inflammatory bowel disease drug, the company's lead product candidate.

    5. UPDATE 2-FDA panel supports approval of Glaxo lung drug Anoro

      Headlines

      Tue, 10 Sep 2013

      WASHINGTON, Sept 10 (Reuters) - A federal advisory panel recommended approval of GlaxoSmithKline Plc 's new drug to treat chronic obstructive pulmonary disease(COPD), but suggested the company be...

    6. FDA panel votes in favor of approval of Glaxo lung drug Anoro

      Headlines

      Tue, 10 Sep 2013

      WASHINGTON, Sept 10 (Reuters) - An federal advisory panel has recommended that the U.S. Food and Drug Administration approve a drug made by GlaxoSmithKline Plc and Theravance Inc to treat chronic...

    7. Safety data on Glaxo COPD drug inconclusive -FDA staff

      Headlines

      Fri, 6 Sep 2013

      Sept 6 (Reuters) - An experimental drug to treat chronic obstructive pulmonary disease made by GlaxoSmithKline Plc and Theravance Inc appears to work, but its safety data are not entirely conclusive,...

    8. Sarepta shares jump after disappointing test for rival drug

      Headlines

      Fri, 16 Aug 2013

      (Reuters) - Shares of Sarepta Therapeutics Inc opened 6.9 percent higher after GlaxoSmithKline Plc reported disappointing clinical data for a rival therapy to Sarepta's experimental muscle disorder...

    9. Sarepta shares jump after disappointing test for rival drug

      Headlines

      Fri, 16 Aug 2013

      Aug 16 (Reuters) - Shares of Sarepta Therapeutics Inc opened 6.9 percent higher after GlaxoSmithKline Plc reported disappointing clinical data for a rival therapy to Sarepta's experimental muscle...

    10. BRIEF-GlaxoSmithKline launches $50 mln venture capital fund

      Headlines

      Thu, 8 Aug 2013

      Aug 8 (Reuters) - GlaxoSmithKline Plc : * GSK launches $50 million venture capital fund toinvest in pioneering

    « Prev12Next »
    Content Partners